Significant new investment from Nestlé Health Science.
‘Four years after opening for business, a subsidiary of Nestlé specializing in nutritional therapy is striking one of its most prominent investments to date with a bet on experimental treatments for the bacteria within the human body.
Nestlé Health Science plans to announce on Tuesday that it has invested $65 million in Seres Health, a start-up based in Cambridge, Mass., that focuses on restoring the “microbiome” — the host of microorganisms that provide vital functions for humans. The company’s current focus includes treatments for infectious diseases as well as metabolic and inflammatory illnesses.’
Source : DealBook of the NYT
Andromede Ventures 